Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL
06 févr. 2023 08h30 HE
|
Optimi Health Corp.
The Company is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi’s scalable, proprietary production method. Optimi is also manufacturing MDMA under...
Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health
06 oct. 2022 12h51 HE
|
Optimi Health Corp.
Highlights: The safe supply of psychedelic drug products manufactured at a GMP-level is critical in treating serious mental health issues. Minister of Mental Health and Addictions, the Honourable...
Optimi Health Provides Progress Report On Year Of Commercialization
01 sept. 2022 09h00 HE
|
Optimi Health Corp.
Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertise VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:...
Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center
30 août 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health...
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.
27 mai 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 27, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural,...